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We studied the activity of combined oxaliplatin and ﬂuorouracil-leucovorin in 16 consecutive patients with advanced biliary
tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% conﬁdence interval, 29–84%)
and the median overall survival time was 9.5 months (range 0.9–26.8+). Therefore, this regimen might be active in biliary
adenocarcinomas with further evaluation necessary.
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While surgery currently provides the only curative treatment
option in tumours of the biliary system, the majority of patients
is diagnosed with advanced stages of disease. Patients with stage
IV (UICC) gallbladder carcinoma with distant metastases or with
unresectable biliary carcinomas only treated by best supportive
care, have a poor prognosis with a median survival time of less
than 3 months (Pitt et al, 1997; Hejna et al, 1998).
However, in these tumour entities, palliative chemotherapy with
single agents or combination therapies result in partial responses in
about 10 to 20% of patients (Hejna et al, 1998). Moreover, inno-
vative treatment modalities other than chemotherapy like
photodynamic therapy have yielded preliminary beneﬁcial results
only in local tumour control but not for metastatic disease (Ortner
et al, 1998). External beam radiation and brachytherapy have only
demonstrated efﬁcacy in individual patients (Hejna et al, 1998).
Based on the preclinical evidence that oxaliplatin combined with
5-FU-LV possesses remarkable synergistic cytotoxicity in various
human malignancies (Raymond et al, 1997), this prospective phase
II trial was initiated to investigate for the ﬁrst time, to the best of
our knowledge, the activity and safety proﬁle of this combination
therapy for advanced biliary system adenocarcinomas.
PATIENTS AND METHODS
This prospective multicentre study enrolled 16 consecutive patients
with histologically or cytologically conﬁrmed adenocarcinomas of
thegallbladderortheintrahepaticorextrahepaticbiliarytractbetween
November 1997 and May 2001. All patients had locally advanced,
unresectable or metastatic disease and fulﬁlled the standard eligibility
criteria (Raderer et al, 1999). The trial protocol was approved by the
ethics committee of the University of Tu ¨bingen, and written consent
was obtained from all patients before study entry.
The patients received the 2 weekly administered FOLFOX 3 regi-
men (Andre ￿ et al, 1998) including l-OHP 85 mg m
72 per 2 h on
day 1 concurrent with LV 500 mg m
72 per 2 h, followed by
continuous 5-FU infusion 1.5 to 2.0 g m
72 per 22 h on days 1–
2. Objective tumour evaluation for response was performed at 9
week intervals according to WHO standard criteria (World Health
Organization, 1979).
Statistics
Overall survival (OS) was calculated from the initiation of
chemotherapy until death. Time to progression (TTP) was deter-
mined by the interval between the start of chemotherapy and the
date of objectively measured disease progression, or the occurence
of death by any cause. Statistical analysis was performed using
SPSS for Windows 10.0 (SPSS, Inc., Chicago, IL, USA). Median
OS and TTP were estimated according to the Kaplan–Meier meth-
od (Kaplan & Maier, 1959).
RESULTS
Patients characteristics are detailed in Table 1.
A total of 146 courses were administered (median 7, range 2 to
19). Thirty courses (21%) were delayed for at least 1 week due to
unresolved haematologic (20 cycles) and non-haematologic
(10 cycles) side effects. The median cumulative doses for oxalipla-
tin and 5-FU were 595 mg m
72 (range 170–1.615 mg m
72) and
12.350 mg m
72 (range 3.000–21.600 mg m
72) corresponding to
92.4 and 85.9% of the planned doses, respectively.
Fourteen of the 16 patients were evaluable for response by
radiological imaging, including one patient who was withdrawn
from the study after seven cycles due to an allergic reaction to
oxaliplatin. In this patient response and survival were calculated
on an intent-to-treat basis. Two other patients dying from rapid
progressive disease after two or three treatment courses were
included as non-responders.
Three patients (19%) achieved a partial response (95% CI, 0%
to 41%) and six (37.5%) stable disease (95% CI, 11% to 64%).
From initiation of chemotherapy, actuarial estimation of median
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0 to 11.3 months) and 9.5 months (range 0.9 to 26.8+) (95% CI,
0.4 to 18.6 months), respectively. At the end-point of this study
three patients were still alive.
All 16 patients were evaluable for toxic effects on 146
courses. No toxic deaths occured on the study. Both WHO
grade 4 adverse reactions (thrombocytopenia and non-febrile
leukopenia) as well as grade 3 toxicities (thrombocytopenia,
mucositis and infection) were experienced in less than 2% of
cycles, respectively. The main grade 3 toxic effect was peripheral
sensory neuropathy that was noted in three patients (4.8% of
cycles). One patient experienced a febrile allergic reaction to
oxaliplatin at the sixth treatment course. In the following cycle,
therapy was given without oxaliplatin and was well tolerated,
whereas re-introduction of oxaliplatin resulted in a febrile aller-
gic reaction again. The patient was therefore withdrawn from
the study.
DISCUSSION
The search is on for novel options in the palliative treatment of
advanced adenocarcinomas of the biliary system. Thus, in the
present prospective phase II trial, we assessed the efﬁcacy and toxi-
city proﬁles of a 2 weekly schedule of l-OHP combined with high-
dose 5-FU-LV (FOLFOX-3 regimen) given on outpatient basis in
this setting. Our results regarding efﬁcacy, showing a disease
control rate (responses and stable disease) of 56% and a median
OS time of 9.5 months, are encouraging.
In previous studies for biliary tract tumours, including 5-FU-LV
with or without etoposide (Glimelius et al, 1996), single-agent
docetaxel (Papakostas et al, 2001) or weekly gemcitabine
(1.200 mg m
72 and 1.000 mg m
72, respectively) (Raderer et al,
1999; Gebbia et al, 2001), median OS times have been reported
in the range of 6.5 to 8 months, respectively. In two phase II trials,
both including only small numbers of patients, gemcitabine plus
5-FU/LV and 2 weekly high-dose gemcitabine (2.200 mg m
72)
yielded disease control rates of 59 and 66%, respectively (Gebbia
et al, 2001; Penz et al, 2001).
Nevertheless, there is a need for larger study populations and
randomized trials conﬁrming these results. Of note, the underlying
molecular mechanism of synergistic action of l-OHP plus 5-FU-LV
combination therapy is completely different to the nucleoside
analogue gemcitabine. Therefore, both regimens might be used
for the treatment of advanced biliary carcinomas alternatively or
as a sequential therapeutical approach, that might be addressed
in future studies.
The toxic effects noted in our study are in accordance with
those observed with the FOLFOX-3 regimen for the treatment of
colorectal carcinoma (Andre ￿ et al, 1998) showing that this schedule
is well tolerated.
In summary, this phase II trial suggests that oxaliplatin
combined with 5-FU-LV is active and well tolerated in adenocarci-
nomas of the biliary system. Further studies, including an
assessment in terms of quality of life, are required.
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Table 1 Patient characteristics
Characteristic No. of patients (%)
Number of patients entered 16 (100)
Age (years)
Median 63
Range 38–74
Sex
Male 10 (62.5)
Female 6 (37.5)
ECOG performance status
0 8 (50)
1 5 (31)
2 3 (19)
Site of the primary tumour
Gallbladder 7 (44)
Intrahepatic bile ducts 7 (44)
Extrahepatic bile ducts 2 (13)
Sites of metastases
Liver 15 (94)
Lymph nodes 9 (56)
Lung 3 (19)
Peritoneum 2 (13)
Other 3 (19)
Number of metastatic sites
1 5 (31)
52 11 (69)
Prior treatment
Radiotherapy 1 (6)
Surgery 4 (25)
None 11 (69)
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